Anti-Mouse CD370 (CLEC9A/DNGR1) - Purified In vivo PLATINUM Functional Grade

Antibody Details

Product Details

Reactivity Species

Mouse

Host Species

Mouse

Immunogen

RBL-2H3 cells expressing mouse DNGR-1 fused to an HA epitope

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 0.5 EU/mg as determined by the LAL method

Purity

≥95% monomer by analytical SEC

⋅

> 95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM^TM antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

Next Day 2-8°C

RRID

AB_2893830

Applications and Recommended Usage?
Quality Tested by Leinco

FC
WB

Other Applications Reported In Literature ?

IF

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

This clone 1F6 monoclonal antibody recognizes a direct epitope on mouse DNGR1/CLEC9A for CD8+ dendritic cells, which can be exploited for tumor therapy, whilst also recognizing necrotic cells. This antibody can recognize both the short and long isoform of DNGR-1, which varies in a segment of the stalk region.

Antigen Distribution

CD370 (CLEC9A) in mice is expressed on CD8+ DCs and at low levels by plasmacytoid DCs

Background

CLEC9A antibody, 1F6, recognizes C-type lectin domain family 9 member A (CLEC9A), also known as CD370 and DNGR-1. CLEC9A is a type II transmembrane glycoprotein that belongs to the C-type lectin superfamily. In mice and humans, CLEC9A is expressed by CD8a+ conventional dendritic cells (cDCs) in mice^{1, 2} and BDCA3+ DCs in humans³, which are specialized for the cross-presentation of exogenous antigens on MHC class I⁴. In mice, type I interferon (IFN)-secreting plasmacytoid DCs (pDCs) also express CLEC9A². The ligand for CLEC9A is filamentous actin exposed on apoptotic cells^{5, 6}, and ligation of CLEC9A results in the cross-presentation and induction of CD8 T cell responses. CLEC9A is a target for vaccine enhancement, and antibodies targeting CLEC9A in vaccination studies lead to enhanced presentation by DCs, eliciting CD8 and CD4 T cell proliferation and strong humoral immunity. In addition, antigen targeting DCs via CLEC9A can enhance anti-tumor immunity¹².

Antigen Details

Protein

CD370

PubMed

CD370

NCBI Gene Bank ID

232414

Research Area

Immunology

.

Innate Immunity

References & Citations

1. Murphy KM, et al. (2012) Blood. 119(25):6052–62

2. Ahmet F, et al. (2008) Blood. 112(8):3264-3273

3. Brown GD, et al. (2008) J Biol Chem. 283(24):16693-701

3. Bevan MJ, et al. (2000) J Exp Med. vol. 192 (pg. 1685-1696)
4. Feest C, et al. (2012) Immunity. 36(4):635–45

5. Kitsoulis S, et al. (2012) Immunity. 36(4):646–57

6. Huang Y, et al. (2011) PNAS. 108(6):2384–9

7. Chan CEZ, et al. (2017) 2:31

8. Joffre OP, et al. (2010) Eur J Immunol. 40(5):1255–65

10. Lahoud M., et al. (2015) Eur. J. Immunol. 45:854–864

11. Caminschi I., et al. (2011) J Immunol. 187(2):842-50

12. Reis e Sousa C., et al. (2008) J Clin Invest. 118(6):2098-110

Technical Protocols